Please login to the form below

Not currently logged in
Email:
Password:

Orphan Drug

Sponsored by

Finalist

Vidaza

Celgene


Summary of work

Azacitidine (Vidaza), the first licensed treatment for the management of Intermediate-2 and high-risk Myelodysplastic Syndromes (MDS) across Europe, was seen by clinicians as a breakthrough treatment for patients with limited other options. However, prior to the positive NICE appraisal for Vidaza in February 2011, there was limited experience of prescribing of Vidaza outside the MDS centres of Excellence and larger teaching hospitals. Therefore, following the positive NICE recommendation, Celgene initiated a three-pronged customer support programme, focusing on clinicians, nurses and pharmacists based in District General Hospitals (DGH), to ensure all patients across England were able to access the treatment on the NHS. 

The support programme, based on critical insights from European markets where Vidaza was widely-used and existing prescribers and UK clinical trialists, focused on: 

  • Patient identification and diagnosis 
  • Initiation and maintaining patients on treatment 
  • Administration and side effect management. 

By the end of 2011, sales of Vidaza had trebled with 35 per cent of all eligible patients initiated on the treatment. In addition, the number of cycles of treatment per patient increased throughout the year – testament to the support programme Celgene had invested in.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...